These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 9086441)

  • 41. [MMIP chemotherapy for the treatment of the relapsed and refractory non-Hodgkin's lymphoma].
    Takeshima M; Nakamura S; Mochizuki Y; Hattori N; Kaya H; Otake S; Okabe Y; Okumura H; Yoshida T; Matano S
    Rinsho Ketsueki; 1995 Feb; 36(2):106-14. PubMed ID: 7715081
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Bendamustine, vincristine, prednisolone (BOP) in therapy of advanced low-grade non-Hodgkin lymphoma]].
    Kath R; Blumenstengel K; Fricke HJ; Peters HD; Höffken K
    Dtsch Med Wochenschr; 2001 Feb; 126(8):198-202. PubMed ID: 11256023
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
    Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS
    Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase II study of cytarabine and etoposide in children with refractory or relapsed non-Hodgkin's lymphoma: a study of the French Society of Pediatric Oncology.
    Gentet JC; Patte C; Quintana E; Bergeron C; Rubie H; Pein F; Demaille MC; Philip T; Raybaud C
    J Clin Oncol; 1990 Apr; 8(4):661-5. PubMed ID: 2313335
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ifosfamide- and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma.
    Mayer J; Vásová I; Korístek Z; Navrátil M; Klabusay M; Doubek M; Vorlícek J; Cernilová I; Vodvárka P; Petráková K
    Eur J Haematol Suppl; 2001 Jul; 64():21-7. PubMed ID: 11486396
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [IEMAD (modified MIME) therapy for refractory or relapsed non-Hodgkin's lymphoma].
    Li HH; Wu XX; Wang QS; Zhao Y; Bo J; Wang SH; DA WM; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Apr; 14(2):298-300. PubMed ID: 16638201
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma.
    Musolino A; Perrone MA; Michiara M; Delnevo D; Franciosi V; Di Blasio B; Ceci G; Camisa R; Ardizzoni A; Cocconi G
    Cancer; 2005 May; 103(10):2109-17. PubMed ID: 15803492
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase II study of sequential topotecan and etoposide in patients with intermediate grade non-Hodgkin's lymphoma: a National Cancer Institute of Canada Clinical Trials Group study.
    Crump M; Couban S; Meyer R; Rudinskas L; Zanke B; Gluck S; Maksymiuk A; Hoskins P; Matthews S; Eisenhauer E
    Leuk Lymphoma; 2002 Aug; 43(8):1581-7. PubMed ID: 12400600
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma.
    Aurlien E; Holte H; Pharo A; Kvaløy S; Jakobsen E; Smeland EB; Kvalheim G
    Bone Marrow Transplant; 1998 May; 21(9):873-8. PubMed ID: 9613778
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer.
    Krigel RL; Palackdharry CS; Padavic K; Haas N; Kilpatrick D; Langer C; Comis R
    J Clin Oncol; 1994 Jun; 12(6):1251-8. PubMed ID: 8201386
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma.
    Haq R; Sawka CA; Franssen E; Berinstein NL
    Leuk Lymphoma; 1999 Nov; 35(5-6):527-36. PubMed ID: 10609790
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Feasibility of salvage chemotherapy for refractory or relapsed non-Hodgkin's lymphoma with two topoisomerase II inhibitors, MST-16 and VP-16. MST-16 Study Group.
    Kagami Y; Ariyoshi Y; Horiuchi A; Kanamaru A; Kano Y; Naoe T; Oguro M; Ohno R; Sampi K; Shirakawa S; Masaoka T; Furue H
    Int J Hematol; 1996 Oct; 64(3-4):221-9. PubMed ID: 8923784
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dose-intensive ifosfamide for the treatment of non-Hodgkin's lymphoma.
    Vose JM
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):33-7. PubMed ID: 8677446
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Results of a salvage regimen in refractory or relapsed non-Hodgkin's lymphoma.
    Buzzoni R; Colleoni M; Nelli P; Nolè F; Bajetta E
    Leuk Lymphoma; 1994 Jun; 14(1-2):121-8. PubMed ID: 7920218
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The rationale of therapy with mitoxantrone in non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Co-operative Study Group, (NHLCSG) Italy.
    Chisesi T
    Leuk Lymphoma; 1993 Jan; 9(1-2):63-9. PubMed ID: 8477203
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase III comparative trial using CHOP vs CIOP in the treatment of advanced intermediate-grade non-Hodgkin's lymphoma.
    Zinzani PL; Martelli M; Storti S; Musso M; Cantonetti M; Leone G; Cajozzo A; Papa G; Iannitto E; Perrotti A
    Leuk Lymphoma; 1995 Oct; 19(3-4):329-35. PubMed ID: 8535227
    [TBL] [Abstract][Full Text] [Related]  

  • 57. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma.
    Wilson WH; Bryant G; Bates S; Fojo A; Wittes RE; Steinberg SM; Kohler DR; Jaffe ES; Herdt J; Cheson BD
    J Clin Oncol; 1993 Aug; 11(8):1573-82. PubMed ID: 7687667
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Feasibility of high-dose chemotherapy without stem cell support as a first-line treatment for non-Hodgkin's aggressive lymphoma: a pilot study.
    Inoue R; Natazuka T; Shimoyama M; Tamekane A; Kajimoto Y; Iwata N; Matsuoka H; Chihara K; Matsui T
    Leuk Lymphoma; 2000 Jan; 36(3-4):315-21. PubMed ID: 10674903
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase II study of intravenous idarubicin in unfavorable non-Hodgkin's lymphoma.
    Case DC; Gerber MC; Gams RA; Crawford J; Votaw ML; Higano CS; Pruitt BT; Gould J
    Leuk Lymphoma; 1993; 10 Suppl():73-9. PubMed ID: 8481674
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ifosfamide plus mitoxantrone as salvage treatment in non-Hodgkin's lymphomas.
    Lorusso V; Paradiso A; Guida M; Berardi F; De Lena M
    Am J Clin Oncol; 1991 Dec; 14(6):492-5. PubMed ID: 1957837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.